[After the COVID-19 pandemic-Which new vaccinations for adults are available or coming soon?]

A Kwetkat, A Leischker, A-S Endres, H J Heppner

Abstract readEnglish AbstractReview

In one paragraph

Review in Innere Medizin (Heidelberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.3field-weighted citation impact, top 38% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

A KwetkatKlinik für Geriatrie und Palliativmedizin, Klinikum Osnabrück GmbH, Am Finkenhügel 1, 49076, Osnabrück, Deutschland. anja.kwetkat@klinikum-os.de.

A LeischkerAG Impfen der Deutschen Gesellschaft für Geriatrie e. V., Berlin, Deutschland.

A-S EndresAG Impfen der Deutschen Gesellschaft für Geriatrie e. V., Berlin, Deutschland.

H J HeppnerAG Impfen der Deutschen Gesellschaft für Geriatrie e. V., Berlin, Deutschland.

Asklepios Fachklinikum Brandenburg · DEEvangelische Hochschule Berlin · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEKlinikum Osnabrück · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The accumulation of respiratory infections in the winter months repeatedly highlights the relevance of prevention through vaccination, even beyond a pandemic. Current developments in this field are therefore highly relevant, particularly for older people who are more susceptible to infections due to immune senescence and comorbidities. The Standing Committee on Vaccination (STIKO) has responded accordingly by recommending the 20-valent pneumococcal conjugate vaccine PCV20 for standard and indication vaccination of adults. Furthermore, new vaccines against respiratory syncytial virus (RSV) infections are available for which the STIKO has not yet issued a recommendation. The development of other more effective and more immunogenic vac2cines is being driven in particular by new technologies, such as mRNA or vector vaccines. Various higher valent pneumococcal vaccine candidates and, for example, universal influenza vaccines are also already in development.

Indexed as

COVID-19Influenza VaccinesAdultAgedHumansPandemicsPneumococcal VaccinesVaccinationInfluenza VaccinesPneumococcal VaccinesDengue vaccinesInfluenza vaccines/universalMultiple antigen-presenting systemPneumococcal conjugate vaccinesRespiratory syncytial virus vaccines

Identifiers

PMID38108878

DOI10.1007/s00108-023-01640-9

OpenAlexW4389893822

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.